Skip to content

Trial Summary

This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator’s choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.



ACTRN/NCT /ethics:


Scientific title:

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

Sponsor / Cooperative group:

Alkermes, Inc.

Trial & Patient Characteristics

Cancer TypeFemale reproductive system
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
Tumour Stream -
Cancer Stage-
Anticipated Start Date2022-01-10
Anticipated End Date2026-12-01

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead/Kate Penta
Phone08 8359 2565
Principal InvestigatorMeena Okera
Recruitment StatusRecruiting